Ulipristal acetate, 5 mg: A new alternative;Acetato de ulipristal 5 mg: Una nueva alternativa

Medicina Clinica

Volumn 141, Issue SUPPL.1, 2013, Pages 40-46

  Sancho, Javier Monleón ^a   Romaguera, Eugenia ^a   Romero, Ainhoa ^a   Higueras, Gema ^a   Morcillo, Inmaculada ^a   Fuster, Sonia ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Conservative treatment; Esmya; Fibroid; Preoperative treatment; SPRM; Ulipristal acetate

Indexed keywords

AROMATASE INHIBITOR; LEUPRORELIN; PLACEBO; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR MODULATOR; ULIPRISTAL;

AMENORRHEA; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CONSERVATIVE TREATMENT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE STERILITY; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; LEIOMYOMA; PREOPERATIVE TREATMENT; RADIOFREQUENCY ABLATION; UTERINE ARTERY EMBOLIZATION;

EID: 84890064054     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/S0025-7753(13)70052-6     Document Type: Article

References (29)

1. Levy B. Modern management of uterine fibroids. Acta Obstet Gynecol. 2008;87: 812-23.
2. Pritts EA, Parker WH, Olive DL. Fibroids and infertility: an updated systematic review of the evidence. Fertil Steril. 2009;91:1215-23.
3. Leibsohn S, D'Ablaing G, Mishell DR Jr, Schlaerth JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol. 1990;162:968-76. (Pubitemid 20155415)
4. Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol. 1994;83:41-8.
5. The Practice Committee of the American Society for Reproductive Medicine in collaboration with The Society of Reproductive Surgeons. Myomas and reproductive function. Fertil Steril. 2008;90:S125-30.
6. Sunkara SK, Khairy M, El-Toukhy T, Khalaf Y, Coomarasamy A. The effect of intramural fibroids without cavity involvement on the outcome in IVF treatment: a systematic review and meta-analysis. Hum Reprod. 2010;25:418-29.
7. Ardaens-Boulier K. Fibromes et contraception. Réalités en gynécologie-obstétrique. 2011;152:1-6.
8. Zapata LB, Whiteman MK, Tepper NK, Jamieson DJ, Marchbanks PA, Curtis KM. Intrauterine device use among women with uterine fibroids: systematic review. Contraception. 2010;821:41-55.
9. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev. 2000:CD000249.
10. Lethaby A, Vollenhoven B, Sowter M. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. BJOG. 2002;109:1097-108. (Pubitemid 35287078)
11. Parsanezhad ME, Azmoon M, Alborzi S, Rajaeefard A, Zarei A, Kazerooni T, et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril. 2010;93:192-8.
12. Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SS. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab. 1993;76:513.
13. Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol. 2006;108:1381.
14. Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol. 2005;12:227.
15. Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update. 2005;11:293-307. (Pubitemid 40674206)
16. Madauss KP, Grygielko ET, Deng SJ, Sulpizio AC, Stanley TB, Wu C, et al. A Structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. Mol Endocrinol. 2007;21:106681.
17. FDA Background document for meeting of advisory committee for reproductive health drugs. Jun 17, 2010. NDA 22-474 Ulipristal Acetate (Proposed trade name: Ella). HRA Pharma. December 15, 2010.
18. Kim A, Barna Bridgeman M. A selective progesterone receptor modulator for emergency contraception. 2011;36:325-31.
19. Mutter GL, Bergeron C, Deligdisch L, Ferenczy A, Glant M, Merino M, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol. 2008;21:591-8. (Pubitemid 351589653)
20. Spitz IM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol. 2009;21:318-24.
21. Engman M, Skoog L, Söderqvist G, Gemzell-Danielsson K. The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Human Reprod. 2008;23:2072-9.
22. Communal L, Vilasco M, Hugon-Rodin J, Courtin A, Mourra N, Lahlou N, et al. Ulipristal acetate does not impacthuman normal breast tissue. Human Reprod. 2012;27:2785-98.
23. Wiehle R, Lantvit D, Yamada T, Christov K. CDB-4124, a progesterone receptor modulator, inhibits mammary carcinogenesis by suppressing cell proliferation and inducing apoptosis. Cancer Prev Res (Phila). 2011;4:414-23.
24. Xu Q, Takekida S, Ohara N, Chen W, Sitruk-Ware R, Johansson ED, et al. Progesterone receptor modulator CDB-2914down-regulates proliferative cell nuclear antigen and Bcl-2 proteinexpression and up-regulates caspase-3 and poly(adenosine5'-diphosphate-ribose) polymerase expression in cultured humanuterine leiomyoma cells. J ClinEndocrinol Metab. 2005;90:953-61. (Pubitemid 40279221)
25. Yoshida S, Ohara N, Xu Q, Chen W, Wang J, Nakabayashi K, et al. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Semin Reprod Med. 2010;28:260-73.
26. Horak P, Mara M, Dundr P, Kubinova K, Kuzel D, Hudecek R, et al. Effect of a selective progesterone receptor modulator on induction of apoptosis in uterine fibroids in vivo. Int J Endocrinol. 2012;43:74.
27. Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366:409-20.
28. Donnez J, Tomaszewski J, Vázquez F, Bouchard P, Lemieszczuk B, Baró F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012;366:421-32.
29. Musallam KM, Tamim HM, Richards T, Spahn DR, Rosendaal FR, Habbal A, et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet. 2011;378,1396-407.